The company has signed a non-exclusive licensing agreement with Gilead Sciences earlier in 2015
Natco Pharma has launched the first licensed generic version of ledipasvir+sofosbuvir combination in Nepal, under its brand name Hepcinat.
Ledipasvir+Sofosbuvir is a two-drug fixed-dose combination product that contains 90 mg of ledipasvir and 400 mg of sofosbuvir in a single tablet, and sold globally by Gilead Sciences, under its brand HARVONI. It is indicated for the treatment of chronic hepatitis C (CHC) genotype 1 infection in adults. NATCO priced its generic medicine, Hepcinat, at an MRP of Rs 25,000 for a bottle of 28 tablets in Nepal.
Natco had signed a non-exclusive licensing agreement with Gilead Sciences earlier in 2015, to manufacture and sell generic versions of its chronic hepatitis C medicines, including generic version of HARVONI, in India and other 100 developing countries.